- Knowledge center
Adoptive cell therapies, spearheaded by chimeric antigen receptor (CAR) T-cell therapy, are showing promise as innovative ways of treating patients with hematological malignancies and solid tumors including melanoma, breast cancer and sarcoma. Developing such a therapeutic presents substantial challenges including:
Additionally, since the genetic manipulation of autologous immune cells typically relies on the use of viral vectors , it is essential to:
To address some of these challenges Biogazelle has developed specific adoptive cell therapy workflows for VCN determination, replication competent retrovirus (RCR) or lentivirus (RCL) detection, as well as CAR-T and CAR-NK cell quantification. We can develop a test for any target of interest, validated as needed to fulfill your quality and regulatory requirements and thus offer a more sensitive alternative to immunohistochemistry for the analysis of the biodistribution of your CAR-T or CAR-NK cells.
Our workflows make use of highly sensitive and accurate PCR-based methods. Biogazelle’s founders are internationally recognized qPCR experts and our company has been at the forefront of digital PCR-based research since 2013. We serve as a reference laboratory for Bio-Rad’s QX200 Digital Droplet PCR system in Europe and use our experience to provide digital PCR services both in clinical research and clinical trial settings.
Some examples of our track record in the adoptive cell therapy area include: